IUPAC name
N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl) methoxy]quinazolin-4-amine
VANDETANIB
CAS No.
443913-73-3
Molecular Weight
475.4 g·mol−1
Molecular Formula
C22H24BrFN4O2
Granule: Available
Ready to press þ
Ready to fill o
Mechanism Of Action:
Vandetanib is a selective and potent inhibitor of VEGFR (vascular endothelial growth factor receptor), EGFR (epidermal growth factor receptor) and RET (RE-arranged during Transfection) tyrosine kinases.
EGFR- and VEGFR-dependent signaling are both clinically validated pathways in cancer, including non-small-cell lung cancer. RET activity is important in some types of thyroid cancer, and early data with vandetanib in medullary thyroid cancer led to orphan-drug designation by the regulatory authorities in the USA and EU.
Indication:
It indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.
*Use in patients with indolent, asymptomatic or slowly progressing disease only after careful consideration of the treatment related risks.